By Samuel Indyk
Investing.com – Omega Diagnostics (LON:) has said that a study of its Mologic lateral flow antigen test has provided “positive” results.
The study, titled “Accuracy of the Mologic COVID-19 rapid antigen test: a prospective multi-centre analytical and clinical evaluation”, concluded that the Mologic test has fulfilled the World Health Organization target diagnostic accuracy with a high sensitivity (93.2%-98.4%) detecting individuals with high viral load infections.
“This is great news for the Mologic test, which we are now producing under our VISITECT brand,” said Omega Diagnostics CEO Colin King. “It is significant that the test has been shown to have high diagnostic accuracy, but also that this performance is replicated across multiple different settings, different demographics, and on self-collected swab specimens.”
The Mologic test provides healthcare professionals with an accurate rapid test for detection in just 10 minutes.
It is hoped by governments, advisers, and healthcare professionals that rapid testing for COVID-19 can enable life to return to normal, due to identifying infections early and slowing the spread.
There is also hope that some large scale events, such as sporting events and music concerts and festivals, could benefit from rapid testing.
“As we continue to make good progress on our vaccine program and with our roadmap to cautiously easing restrictions underway, regular rapid testing is even more important to make sure those efforts are not wasted,” UK Prime Minister Boris Johnson said in April.
At 09:10BST, shares in Omega Diagnostics were trading higher by 1.4% at 66.93 pence per share.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.